MARKET

QLGN

QLGN

Qualigen Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.340
-0.090
-2.62%
After Hours: 3.420 +0.08 +2.40% 18:31 03/02 EST
OPEN
3.500
PREV CLOSE
3.430
HIGH
3.550
LOW
3.330
VOLUME
655.11K
TURNOVER
--
52 WEEK HIGH
21.50
52 WEEK LOW
2.870
MARKET CAP
89.20M
P/E (TTM)
-0.7134
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
BRIEF-Qualigen Therapeutics Secures Option To Negotiate License For G-Quadruplex Anti-Cancer Technology From Ucl
reuters.com · 1d ago
Qualigen Therapeutics Secures Option to Negotiate License for G-Quadruplex Anti-Cancer Technology from UCL
CARLSBAD, Mar 01, 2021 (GLOBE NEWSWIRE via COMTEX) -- CARLSBAD, Calif., March 01, 2021 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (NASDAQ: QLGN), a...
GlobeNewswire · 1d ago
Best Penny Stocks To Buy Before Friday? 4 Under $4 To Watch
Feb 24, 2021 (Penny Stocks via COMTEX) -- 4 Penny Stocks To Watch With Increased Volume This Month Penny stocks were in direct focus on Wednesday. Partially...
Penny Stocks · 6d ago
Qualigen Therapeutics Announces Completion Of Milestone Related To License and Technology Transfer Of Its FastPack Diagnostics Products In China, Triggering Payment Obligation From Yi Xin Zhen Duan Jishu
CARLSBAD, Calif., Jan. 26, 2021 /PRNewswire/ -- Qualigen Therapeutics, Inc. (NASDAQ:QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral
Benzinga · 01/26 14:02
Qualigen Therapeutics Announces Completion of Milestone Related to the License and Technology Transfer of its FastPack® Diagnostics Products in China
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announces achievement of a milestone event which triggered a payment obligation from Yi Xin Zhen Du...
PR Newswire · 01/26 14:00
Qualigen Therapeutics Announces Completion of Milestone Related to the License and Technology Transfer of its FastPack® Diagnostics Products in China
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announces achievement of a milestone event which triggered a payment obligation from Yi Xin Zhen Du...
PR Newswire · 01/26 14:00
Qualigen Therapeutics Announces Completion of Milestone Related to the License and Technology Transfer of its FastPack® Diagnostics Products in China
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and viral diseases, announces achievement of a milestone event which triggered a payment obligation from Yi Xin Zhen Du...
PR Newswire · 01/26 14:00
APTX, CCIV, MARA and WW among notable premarket gainers
La Jolla Pharmaceutical (LJPC +62% on exclusive licensing agreement with PAIONVOXX International (VOXX +56% after posting strong sales growth.T2 Biosystems (TTOO +33% after the company says its T2SARS-CoV-2 Panel is capable of detecting multiple variants of
Seekingalpha · 01/12 13:23
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of QLGN. Analyze the recent business situations of Qualigen Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average QLGN stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 42
Institutional Holdings: 1.71M
% Owned: 6.40%
Shares Outstanding: 26.71M
TypeInstitutionsShares
Increased
5
115.75K
New
14
285.13K
Decreased
5
18.65K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.03%
Pharmaceuticals & Medical Research
-0.88%
Key Executives
Chairman/President/Chief Executive Officer/Director
Michael Poirier
Chief Financial Officer/Vice President - Finance
Christopher Lotz
Executive Vice President/Director
Amy Broidrick
Chief Scientific Officer/Vice President - Research & Development
Wajdi Abdul-Ahad
Vice President - Operations
Shishir Sinha
Director
Ira Ritter
Independent Director
Richard David
Independent Director
Sidney Emery
Independent Director
Matthew Korenberg
Independent Director
Kurt Kruger
  • Dividends
  • Splits
  • Insider Activity
No Data
About QLGN
Qualigen Therapeutics, Inc., formerly Ritter Pharmaceuticals, Inc., is a biotechnology company. The Company is focused on the development and commercialization of therapeutic products for the treatment of cancer and infectious diseases, as well as development of its FastPack diagnostic platform. Its pipeline includes AS1411, Aptamer Linked Anti Nucleolin (ALAN), Aptamer Linked Anti Nucleolin - Contrast Enhancement (ALAN-CE), Aptamer Linked Anti Nucleolin - Radiation Enhancement (ALAN-RE), Selective Target Antigen Removal System (STARS) and RAS-F. The FastPack System is an immunoassay testing system, which consists of the FastPack Analyzer and the FastPack test pouch, a single-use, disposable, foil packet which includes the FastPack reagent chemistry. The Company’s subsidiary is Qualigen, Inc.

Webull offers kinds of Qualigen Therapeutics Inc stock information, including NASDAQ:QLGN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, QLGN stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading QLGN stock methods without spending real money on the virtual paper trading platform.